Visceral leishmaniasis: Revisiting current treatments and approaches for future discoveries

Acta Tropica

Volumn 155, Issue , 2016, Pages 113-123

  No, Joo Hwan ^a  

^a Institute Pasteur Korea   (South Korea)

Author keywords

Drug discovery; Drug target; Leishmaniasis; Mechanism of Action; Phenotypic assay

Indexed keywords

AMPHOTERICIN B; ANTIMONY; MILTEFOSINE; PAROMOMYCIN; PENTAMIDINE; ANTIPROTOZOAL AGENT;

ANTIBIOTIC RESISTANCE; BIOTECHNOLOGY; DISEASE TREATMENT; DRUG DEVELOPMENT; FUTURE PROSPECT; IMMUNE SYSTEM; LEISHMANIASIS; PHENOTYPE; RESEARCH AND DEVELOPMENT;

DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; DRUG TARGETING; HIGH THROUGHPUT SCREENING; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; NONHUMAN; PHENOTYPE; REVIEW; TREATMENT OUTCOME; VISCERAL LEISHMANIASIS; FORECASTING; LEISHMANIASIS, VISCERAL;

ANTIPROTOZOAL AGENTS; FORECASTING; HUMANS; LEISHMANIASIS, VISCERAL;

EID: 84953322746     PISSN: 0001706X     EISSN: 18736254     Source Type: Journal    
DOI: 10.1016/j.actatropica.2015.12.016     Document Type: Review

References (141)

1. Alvar J., Velez I.D., Bern C., Herrero M., Desjeux P., Cano J., Jannin J., den Boer M., Team WHOLC Leishmaniasis worldwide and global estimates of its incidence. PLoS One 2012, 7:e35671.
2. Anderson T.M., Clay M.C., Cioffi A.G., Diaz K.A., Hisao G.S., Tuttle M.D., Nieuwkoop A.J., Comellas G., Maryum N., Wang S., Uno B.E., Wildeman E.L., Gonen T., Rienstra C.M., Burke M.D. Amphotericin forms an extramembranous and fungicidal sterol sponge. Nat. Chem. Biol. 2014, 10:400-406.
3. Arango Duque G., Descoteaux A. Leishmania survival in the macrophage: where the ends justify the means. Curr. Opin. Microbiol. 2015, 26:32-40.
4. Aripirala S., Gonzalez-Pacanowska D., Oldfield E., Kaiser M., Amzel L.M., Gabelli S.B. Structural and thermodynamic basis of the inhibition of Leishmania major farnesyl diphosphate synthase by nitrogen-containing bisphosphonates. Acta Crystallogr. D Biol. Crystallogr. 2014, 70:802-810.
5. Aszalos A., Bax A., Burlinson N., Roller P., McNeal C. Physico-chemical and microbiological comparison of nystatin, amphotericin A and amphotericin B, and structure of amphotericin A. J. Antibiot. (Tokyo) 1985, 38:1699-1713.
6. Aulner N., Danckaert A., Rouault-Hardoin E., Desrivot J., Helynck O., Commere P.H., Munier-Lehmann H., Spath G.F., Shorte S.L., Milon G., Prina E. High content analysis of primary macrophages hosting proliferating Leishmania amastigotes: application to anti-leishmanial drug discovery. PLoS Negl. Trop Dis. 2013, 7:e2154.
7. Azzouz S., Maache M., Garcia R.G., Osuna A. Leishmanicidal activity of edelfosine, miltefosine and ilmofosine. Basic Clin. Pharmacol. Toxicol. 2005, 96:60-65.
8. Bacellar O., Brodskyn C., Guerreiro J., Barral-Netto M., Costa C.H., Coffman R.L., Johnson W.D., Carvalho E.M. Interleukin-12 restores interferon-gamma production and cytotoxic responses in visceral leishmaniasis. J. Infect. Dis. 1996, 173:1515-1518.
9. Badaro R., Falcoff E., Badaro F.S., Carvalho E.M., Pedral-Sampaio D., Barral A., Carvalho J.S., Barral-Netto M., Brandely M., Silva L., et al. Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N. Engl. J. Med. 1990, 322:16-21.
10. Baiocco P., Colotti G., Franceschini S., Ilari A. Molecular basis of antimony treatment in leishmaniasis. J. Med. Chem. 2009, 52:2603-2612.
11. Basselin M., Coombs G.H., Barrett M.P. Putrescine and spermidine transport in Leishmania. Mol. Biochem. Parasitol. 2000, 109:37-46.
12. Ben Salah A., Ben Messaoud N., Guedri E., Zaatour A., Ben Alaya N., Bettaieb J., Gharbi A., Belhadj Hamida N., Boukthir A., Chlif S., Abdelhamid K., El Ahmadi Z., Louzir H., Mokni M., Morizot G., Buffet P., Smith P.L., Kopydlowski K.M., Kreishman-Deitrick M., Smith K.S., Nielsen C.J., Ullman D.R., Norwood J.A., Thorne G.D., McCarthy W.F., Adams R.C., Rice R.M., Tang D., Berman J., Ransom J., Magill A.J., Grogl M. Topical paromomycin with or without gentamicin for cutaneous leishmaniasis. N. Engl. J. Med. 2013, 368:524-532.
13. Berman J.D., Gallalee J.V., Hansen B.D. Leishmania mexicana: uptake of sodium stibogluconate (Pentostam) and pentamidine by parasite and macrophag. Exp. Parasitol. 1987, 64:127-131.
14. Bhattacharya P., Ali N. Involvement and interactions of different immune cells and their cytokines in human visceral leishmaniasis. Rev. Soc. Bras. Med. Trop. 2013, 46:128-134.
15. Boelaert M., Criel B., Leeuwenburg J., Van Damme W., Le Ray D., Van der Stuyft P. Visceral leishmaniasis control: a public health perspective. Trans. R. Soc. Trop. Med. Hyg. 2000, 94:465-471.
16. Brahmachari U.N. A Treatise on Kala Azar 1928, J. Bale. Sons Dainelsson, London, U.K.
17. Burchmore R.J., Barrett M.P. Life in vacuoles-nutrient acquisition by Leishmania amastigotes. Int. J. Parasitol. 2001, 31:1311-1320.
18. Cammerer S.B., Jimenez C., Jones S., Gros L., Lorente S.O., Rodrigues C., Rodrigues J.C., Caldera A., Ruiz Perez L.M., da Souza W., Kaiser M., Brun R., Urbina J.A., Gonzalez Pacanowska D., Gilbert I.H. Quinuclidine derivatives as potential antiparasitics. Antimicrob. Agents Chemother. 2007, 51:4049-4061.
19. Carrera L., Gazzinelli R.T., Badolato R., Hieny S., Muller W., Kuhn R., Sacks D.L. Leishmania promastigotes selectively inhibit interleukin 12 induction in bone marrow-derived macrophages from susceptible and resistant mice. J. Exp. Med. 1996, 183:515-526.
20. Chawla B., Jhingran A., Panigrahi A., Stuart K.D., Madhubala R. Paromomycin affects translation and vesicle-mediated trafficking as revealed by proteomics of paromomycin -susceptible -resistant Leishmania donovani. PLoS One 2011, 6:e26660.
21. Colotti G., Ilari A. Polyamine metabolism in Leishmania: from arginine to trypanothione. Amino Acids 2011, 40:269-285.
22. Cortazar T.M., Coombs G.H., Walker J. Leishmania panamensis: comparative inhibition of nuclear DNA topoisomerase II enzymes from promastigotes and human macrophages reveals anti-parasite selectivity of fluoroquinolones, flavonoids and pentamidine. Exp. Parasitol. 2007, 116:475-482.
23. Davidson R.N., den Boer M., Ritmeijer K. Paromomycin. Trans. R. Soc. Trop. Med. Hyg. 2009, 103:653-660.
24. Davis B.D. Mechanism of bactericidal action of aminoglycosides. Microbiol. Rev. 1987, 51:341-350.
25. De Muylder G., Ang K.K., Chen S., Arkin M.R., Engel J.C., McKerrow J.H. A screen against Leishmania intracellular amastigotes: comparison to a promastigote screen and identification of a host cell-specific hit. PLoS Negl. Trop. Dis. 2011, 5:e1253.
26. De Rycker M., Hallyburton I., Thomas J., Campbell L., Wyllie S., Joshi D., Cameron S., Gilbert I.H., Wyatt P.G., Frearson J.A., Fairlamb A.H., Gray D.W. Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay. Antimicrob. Agents Chemother. 2013, 57:2913-2922.
27. de Souza W., Rodrigues J.C. Sterol biosynthesis pathway as target for anti-trypanosomatid drugs. Interdiscip. Perspect. Infect. Dis. 2009, 2009. 642502.
28. Demicheli C., Frezard F., Lecouvey M., Garnier-Suillerot A. Antimony(V) complex formation with adenine nucleosides in aqueous solution. Biochim. Biophys. Acta 2002, 1570:192-198.
29. Demicheli C., Frezard F., Mangrum J.B., Farrell N.P. Interaction of trivalent antimony with a CCHC zinc finger domain: potential relevance to the mechanism of action of antimonial drugs. Chem. Commun. (Camb.) 2008, 4828-4830.
30. Denton H., McGregor J.C., Coombs G.H. Reduction of anti-leishmanial pentavalent antimonial drugs by a parasite-specific thiol-dependent reductase, TDR1. Biochem. J. 2004, 381:405-412.
31. Di Cristina G., Caronia G. Sulla terapia della leishmaniosi interna. Pathologica 1915, 7:82-83.
32. Dinesh N., Pallerla D.S., Kaur P.K., Kishore Babu N., Singh S. Exploring Leishmania donovani 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) as a potential drug target by biochemical, biophysical and inhibition studies. Microb. Pathog. 2014, 66:14-23.
33. Edwards K.J., Jenkins T.C., Neidle S. Crystal structure of a pentamidine-oligonucleotide complex: implications for DNA-binding properties. Biochemistry 1992, 31:7104-7109.
34. Fairlamb A.H., Cerami A. Metabolism and functions of trypanothione in the Kinetoplastida. Annu. Rev. Microbiol. 1992, 46:695-729.
35. Fanos V., Cataldi L. Renal transport of antibiotics and nephrotoxicity: a review. J. Chemother. 2001, 13:461-472.
36. Fernandes Rodrigues J.C., Concepcion J.L., Rodrigues C., Caldera A., Urbina J.A., de Souza W. In vitro activities of ER-119884 and E5700, two potent squalene synthase inhibitors, against Leishmania amazonensis: antiproliferative, biochemical, and ultrastructural effects. Antimicrob. Agents Chemother. 2008, 52:4098-4114.
37. Ferreira Cdos S., Martins P.S., Demicheli C., Brochu C., Ouellette M., Frezard F. Thiol-induced reduction of antimony(V) into antimony(III): a comparative study with trypanothione, cysteinyl-glycine, cysteine and glutathione. Biometals 2003, 16:441-446.
38. Fourmy D., Recht M.I., Blanchard S.C., Puglisi J.D. Structure of the A site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. Science 1996, 274:1367-1371.
39. Fujii G., Chang J.E., Coley T., Steere B. The formation of amphotericin B ion channels in lipid bilayers. Biochemistry 1997, 36:4959-4968.
40. Gray K.C., Palacios D.S., Dailey I., Endo M.M., Uno B.E., Wilcock B.C., Burke M.D. Amphotericin primarily kills yeast by simply binding ergosterol. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:2234-2239.
41. Gruszecki W.I., Gagos M., Herec M., Kernen P. Organization of antibiotic amphotericin B in model lipid membranes. A mini review. Cell Mol. Biol. Lett. 2003, 8:161-170.
42. Harhay M.O., Olliaro P.L., Costa D.L., Costa C.H. Urban parasitology: visceral leishmaniasis in Brazil. Trends Parasitol. 2011, 27:403-409.
43. Hendrickx S., Inocencio da Luz R.A., Bhandari V., Kuypers K., Shaw C.D., Lonchamp J., Salotra P., Carter K., Sundar S., Rijal S., Dujardin J.C., Cos P., Maes L. Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol. PLoS Negl. Trop. Dis. 2012, 6:e1664.
44. Hendrickx S., Boulet G., Mondelaers A., Dujardin J.C., Rijal S., Lachaud L., Cos P., Delputte P., Maes L. Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum. Parasitol. Res. 2014, 113:1875-1881.
45. Holmes D. The GHIT fund shows its cards. Nat. Rev. Drug Discov. 2013, 12:894.
46. Jensen R.E., Englund P.T. Network news: the replication of kinetoplast DNA. Annu. Rev. Microbiol. 2012, 66:473-491.
47. Kamhawi S. Phlebotomine sand flies and Leishmania parasites: friends or foes?. Trends Parasitol. 2006, 22:439-445.
48. Kaminski D.M. Recent progress in the study of the interactions of amphotericin B with cholesterol and ergosterol in lipid environments. Eur. Biophys. J. 2014, 43:453-467.
49. Kandpal M., Fouce R.B., Pal A., Guru P.Y., Tekwani B.L. Kinetics and molecular characteristics of arginine transport by Leishmania donovani promastigotes. Mol. Biochem. Parasitol. 1995, 71:193-201.
50. Kandpal M., Tekwani B.L., Chauhan P.M., Bhaduri A.P. Correlation between inhibition of growth and arginine transport of Leishmania donovani promastigotes in vitro by diamidines. Life Sci. 1996, 59:PL75-PL80.
51. Khademvatan S., Gharavi M.J., Saki J. Miltefosine induces metacaspase and PARP genes expression in Leishmania infantum. Braz. J. Infect. Dis. 2011, 15:442-448.
52. Khan M.O. Trypanothione reductase: a viable chemotherapeutic target for antitrypanosomal and antileishmanial drug design. Drug Target Insights 2007, 2:129-146.
53. Krauth-Siegel R.L., Comini M.A. Redox control in trypanosomatids, parasitic protozoa with trypanothione-based thiol metabolism. Biochim. Biophys. Acta 2008, 1780:1236-1248.
54. Kuhlencord A., Maniera T., Eibl H., Unger C. Hexadecylphosphocholine: oral treatment of visceral leishmaniasis in mice. Antimicrob. Agents Chemother. 1992, 36:1630-1634.
55. Legare D., Richard D., Mukhopadhyay R., Stierhof Y.D., Rosen B.P., Haimeur A., Papadopoulou B., Ouellette M. The Leishmania ATP-binding cassette protein PGPA is an intracellular metal-thiol transporter ATPase. J. Biol. Chem. 2001, 276:26301-26307.
56. Lepesheva G.I., Waterman M.R. Sterol 14alpha-demethylase (CYP51) as a therapeutic target for human trypanosomiasis and leishmanias. Curr. Top. Med. Chem. 2011, 11:2060-2071.
57. Liew F.Y., Millott S., Parkinson C., Palmer R.M., Moncada S. Macrophage killing of Leishmania parasite in vivo is mediated by nitric oxide from -arginine. J. Immunol. 1990, 144:4794-4797.
58. Lindgren E., Andersson Y., Suk J.E., Sudre B., Semenza J.C. Public health: monitoring EU emerging infectious disease risk due to climate change. Science 2012, 336:418-419.
59. Lourie E.M., Yorke W. Studies in chemotherapy XXI. The trypanocidal action of certain aromatic diamidines. Ann. Trop. Med. Parasitol. 1939, 33:289-304.
60. Lukes J., Mauricio I.L., Schonian G., Dujardin J.C., Soteriadou K., Dedet J.P., Kuhls K., Tintaya K.W., Jirku M., Chocholova E., Haralambous C., Pratlong F., Obornik M., Horak A., Ayala F.J., Miles M.A. Evolutionary and geographical history of the Leishmania donovani complex with a revision of current taxonomy. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:9375-9380.
61. Lux H., Hart D.T., Parker P.J., Klenner T. Ether lipid metabolism, GPI anchor biosynthesis, and signal transduction are putative targets for anti-leishmanial alkyl phospholipid analogues. Adv. Exp. Med. Biol. 1996, 416:201-211.
62. Maarouf M., Lawrence F., Croft S.L., Robert-Gero M. Ribosomes of Leishmania are a target for the aminoglycosides. Parasitol. Res. 1995, 81:421-425.
63. Maarouf M., Lawrence F., Brown S., Robert-Gero M. Biochemical alterations in paromomycin-treated Leishmania donovani promastigotes. Parasitol. Res. 1997, 83:198-202.
64. Maarouf M., de Kouchkovsky Y., Brown S., Petit P.X., Robert-Gero M. In vivo interference of paromomycin with mitochondrial activity of Leishmania. Exp. Cell Res. 1997, 232:339-348.
65. Marinho Marinho A., Goncalves K.C., Oliveira S.S., Oliveira A.C., Bellio M., d'Avila-Levy C.M., Santos A.L., Branquinha M.H. Miltefosine induces programmed cell death in Leishmania amazonensis promastigotes. Mem. Inst. Oswaldo Cruz 2011, 106:507-509.
66. Matsumori N., Sawada Y., Murata M. Mycosamine orientation of amphotericin B controlling interaction with ergosterol: sterol-dependent activity of conformation-restricted derivatives with an amino-carbonyl bridge. J. Am. Chem. Soc. 2005, 127:10667-10675.
67. Mauricio I.L., Stothard J.R., Miles M.A. The strange case of Leishmania chagasi. Parasitol Today 2000, 16:188-189.
68. McDowell M.A., Sacks D.L. Inhibition of host cell signal transduction by Leishmania: observations relevant to the selective impairment of IL-12 responses. Curr. Opin. Microbiol. 1999, 2:438-443.
69. Mego J.L. Stimulation of intralysosomal proteolysis by cysteinyl-glycine, a product of the action of gamma-glutamyl transpeptidase on glutathione. Biochim. Biophys. Acta 1985, 841:139-144.
70. Meheus F., Balasegaram M., Olliaro P., Sundar S., Rijal S., Faiz M.A., Boelaert M. Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. PLoS Negl. Trop. Dis. 2010, 4.
71. Mehta A., Shaha C. Apoptotic death in Leishmania donovani promastigotes in response to respiratory chain inhibition: complex II inhibition results in increased pentamidine cytotoxicity. J. Biol. Chem. 2004, 279:11798-11813.
72. Mookerjee Basu J., Mookerjee A., Sen P., Bhaumik S., Sen P., Banerjee S., Naskar K., Choudhuri S.K., Saha B., Raha S., Roy S. Sodium antimony gluconate induces generation of reactive oxygen species and nitric oxide via phosphoinositide 3-kinase and mitogen-activated protein kinase activation in Leishmania donovani-infected macrophages. Antimicrob. Agents Chemother. 2006, 50:1788-1797.
73. Moskalenko N., Pershin G.N. Comparative study of the chemotherapeutic effect of paromomycin and monomycin in experimental cutaneous leischmaniasis in albino mice. Farmakol. Toksikol. 1966, 29:90-94.
74. Mosser D.M., Edwards J.P. Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 2008, 8:958-969.
75. Mukherjee A., Padmanabhan P.K., Sahani M.H., Barrett M.P., Madhubala R. Roles for mitochondria in pentamidine susceptibility and resistance in Leishmania donovani. Mol. Biochem. Parasitol. 2006, 145:1-10.
76. Mukhopadhyay R., Dey S., Xu N., Gage D., Lightbody J., Ouellette M., Rosen B.P. Trypanothione overproduction and resistance to antimonials and arsenicals in Leishmania. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:10383-10387.
77. Murray H.W., Delph-Etienne S. Roles of endogenous gamma interferon and macrophage microbicidal mechanisms in host response to chemotherapy in experimental visceral leishmaniasis. Infect. Immun. 2000, 68:288-293.
78. Murray H.W., Delph-Etienne S. Visceral leishmanicidal activity of hexadecylphosphocholine (miltefosine) in mice deficient in T cells and activated macrophage microbicidal mechanism. J. Infect. Dis. 2000, 181:795-799.
79. Murray H.W., Nathan C.F. Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani. J. Exp. Med. 1999, 189:741-746.
80. Murray H.W., Oca M.J., Granger A.M., Schreiber R.D. Requirement for T cells and effect of lymphokines in successful chemotherapy for an intracellular infection. Experimental visceral leishmaniasis. J. Clin. Invest. 1989, 83:1253-1257.
81. Murray H.W., Montelibano C., Peterson R., Sypek J.P. Interleukin-12 regulates the response to chemotherapy in experimental visceral Leishmaniasis. J. Infect. Dis. 2000, 182:1497-1502.
82. Murray H.W., Berman J.D., Davies C.R., Saravia N.G. Advances in leishmaniasis. Lancet 2005, 366:1561-1577.
83. Murray H.W. Cell-mediated immune response in experimental visceral leishmaniasis: II Oxygen-dependent killing of intracellular Leishmania donovani amastigotes. J. Immunol. 1982, 129:351-357.
84. Nagle A.S., Khare S., Kumar A.B., Supek F., Buchynskyy A., Mathison C.J., Chennamaneni N.K., Pendem N., Buckner F.S., Gelb M.H., Molteni V. Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis. Chem. Rev. 2014, 114(22):11305-11347.
85. Napier L.E., Sen Gupta P.C., Sen G.N. The treatment of Kala-Azar by diamidino stilbene: analysis of 101 cases. Indian M. Gaz. 1942, 77:71-74.
86. Neal R.A. The effect of antibiotics of the neomycin group on experimental cutaneous leishmaniasis. Ann Trop. Med. Parasitol. 1968, 62:54-62.
87. Nylen S., Sacks D. Interleukin-10 and the pathogenesis of human visceral leishmaniasis. Trends Immunol. 2007, 28:378-384.
88. Olin-Sandoval V., Moreno-Sanchez R., Saavedra E. Targeting trypanothione metabolism in trypanosomatid human parasites. Curr. Drug Targets 2010, 11:1614-1630.
89. Orenes Lorente S., Gomez R., Jimenez C., Cammerer S., Yardley V., de Luca-Fradley K., Croft S.L., Ruiz Perez L.M., Urbina J., Gonzalez Pacanowska D., Gilbert I.H. Biphenylquinuclidines as inhibitors of squalene synthase and growth of parasitic protozoa. Bioorg. Med. Chem. 2005, 13:3519-3529.
90. Paris C., Loiseau P.M., Bories C., Breard J. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 2004, 48:852-859.
91. Petri W.A. Therapy of intestinal protozoa. Trends Parasitol. 2003, 19:523-526.
92. Plimmer H.G., Thomson M.B. Further results of the experimental treatment of Trypanosomiasis in rats; being a progress of a Committee of the royal society. Proc. R. Soc. 1907, 80:1-10.
93. Podinovskaia M., Descoteaux A. Leishmania and the macrophage: a multifaceted interaction. Future Microbiol. 2015, 10:111-129.
94. Prokopenko V., Kovalishyn V., Shevchuk M., Kopernyk I., Metelytsia L., Romanenko V., Mogilevich S., Kukhar V. Design and synthesis of new potent inhibitors of farnesyl pyrophosphate synthase. Curr. Drug Discov. Technol. 2014, 11:133-144.
95. Puentes S.M., Dwyer D.M., Bates P.A., Joiner K.A. Binding and release of C3 from Leishmania donovani promastigotes during incubation in normal human serum. J. Immunol. 1989, 143:3743-3749.
96. Rai S., Bhaskar Goel S.K., Nath Dwivedi U., Sundar S., Goyal N. Role of efflux pumps and intracellular thiols in natural antimony resistant isolates of Leishmania donovani. PLoS One 2013, 8:e74862.
97. Rakotomanga M., Saint-Pierre-Chazalet M., Loiseau P.M. Alteration of fatty acid and sterol metabolism in miltefosine-resistant Leishmania donovani promastigotes and consequences for drug-membrane interactions. Antimicrob. Agents Chemother. 2005, 49:2677-2686.
98. Rakotomanga M., Blanc S., Gaudin K., Chaminade P., Loiseau P.M. Miltefosine affects lipid metabolism in Leishmania donovani promastigotes. Antimicrob. Agents Chemother. 2007, 51:1425-1430.
99. Reguera R., Balana Fouce R., Cubria J.C., Alvarez Bujidos M.L., Ordonez D. Putrescine uptake inhibition by aromatic diamidines in Leishmania infantum promastigotes. Biochem. Pharmacol. 1994, 47:1859-1866.
100. Ritter U., Frischknecht F., van Zandbergen G. Are neutrophils important host cells for Leishmania parasites??. Trends Parasitol. 2009, 25:505-510.
101. Roatt B.M., Aguiar-Soares R.D., Coura-Vital W., Ker H.G., Moreira N., Vitoriano-Souza J., Giunchetti R.C., Carneiro C.M., Reis A.B. Immunotherapy and Immunochemotherapy in Visceral Leishmaniasis: promising treatments for this neglected disease. Front. Immunol. 2014, 5:272.
102. Rodrigues J.C., Urbina J.A., de Souza W. Antiproliferative and ultrastructural effects of BPQ-OH, a specific inhibitor of squalene synthase, on Leishmania amazonensis. Exp. Parasitol. 2005, 111:230-238.
103. Ruiter G.A., Zerp S.F., Bartelink H., van Blitterswijk W.J., Verheij M. Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anticancer Drugs 2003, 14:167-173.
104. Saha P., Mukhopadhyay D., Chatterjee M. Immunomodulation by chemotherapeutic agents against Leishmaniasis. Int. Immunopharmacol. 2011, 11:1668-1679.
105. Shaked-Mishan P., Ulrich N., Ephros M., Zilberstein D. Novel intracellular SbV reducing activity correlates with antimony susceptibility in Leishmania donovani. J. Biol. Chem. 2001, 276:3971-3976.
106. Shapiro T.A., Englund P.T. Selective cleavage of kinetoplast DNA minicircles promoted by antitrypanosomal drugs. Proc. Natl. Acad. Sci. U. S. A. 1990, 87:950-954.
107. Shapiro T.A. Inhibition of topoisomerases in African trypanosomes. Acta Trop. 1993, 54:251-260.
108. Sharlow E.R., Close D., Shun T., Leimgruber S., Reed R., Mustata G., Wipf P., Johnson J., O'Neil M., Grogl M., Magill A.J., Lazo J.S. Identification of potent chemotypes targeting Leishmania major using a high-throughput, low-stringency, computationally enhanced, small molecule screen. PLoS Negl. Trop. Dis. 2009, 3:e540.
109. Silberstein A. Conformational analysis of amphotericin B-cholesterol channel complex. J. Membr. Biol. 1998, 162:117-126.
110. Singh G., Dey C.S. Induction of apoptosis-like cell death by pentamidine and doxorubicin through differential inhibition of topoisomerase II in arsenite-resistant L. donovani. Acta Trop. 2007, 103:172-185.
111. Singh O.P., Sundar S. Immunotherapy and targeted therapies in treatment of visceral leishmaniasis: current status and future prospects. Front. Immunol. 2014, 5:296.
112. Singh S., Dinesh N., Kaur P.K., Shamiulla B. Ketanserin antidepressant, exerts its antileishmanial action via inhibition of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMGR) enzyme of Leishmania donovani. Parasitol. Res. 2014, 113:2161-2168.
113. Siqueira-Neto J.L., Moon S., Jang J., Yang G., Lee C., Moon H.K., Chatelain E., Genovesio A., Cechetto J., Freitas-Junior L.H. An image-based high-content screening assay for compounds targeting intracellular Leishmania donovani amastigotes in human macrophages. PLoS Negl. Trop. Dis. 2012, 6:e1671.
114. Smorenburg C.H., Seynaeve C., Bontenbal M., Planting A.S., Sindermann H., Verweij J. Phase II study of miltefosine 6% solution as topical treatment of skin metastases in breast cancer patients. Anticancer Drugs 2000, 11:825-828.
115. Sosa N., Capitan Z., Nieto J., Nieto M., Calzada J., Paz H., Spadafora C., Kreishman-Deitrick M., Kopydlowski K., Ullman D., McCarthy W.F., Ransom J., Berman J., Scott C., Grogl M. Randomized, double-blinded, phase 2 trial of WR 279,396 (paromomycin and gentamicin) for cutaneous leishmaniasis in Panama. Am. J. Trop. Med. Hyg. 2013, 89:557-563.
116. Squires K.E., Rosenkaimer F., Sherwood J.A., Forni A.L., Were J.B., Murray H.W. Immunochemotherapy for visceral leishmaniasis: a controlled pilot trial of antimony versus antimony plus interferon-gamma. Am. J. Trop. Med. Hyg. 1993, 48:666-669.
117. Stager S., Joshi T., Bankoti R. Immune evasive mechanisms contributing to persistent Leishmania donovani infection. Immunol. Res. 2010, 47:14-24.
118. Steitz T.A. A structural understanding of the dynamic ribosome machine. Nat. Rev. Mol. Cell Biol. 2008, 9:242-253.
119. Sundar S., Chatterjee M. Visceral leishmaniasis-current therapeutic modalities. Indian J. Med. Res. 2006, 123:345-352.
120. Sundar S., Rosenkaimer F., Murray H.W. Successful treatment of refractory visceral leishmaniasis in India using antimony plus interferon-gamma. J. Infect. Dis. 1994, 170:659-662.
121. Sundar S., Singh V.P., Sharma S., Makharia M.K., Murray H.W. Response to interferon-gamma plus pentavalent antimony in Indian visceral leishmaniasis. J. Infect. Dis. 1997, 176:1117-1119.
122. Sundar S., Jha T.K., Thakur C.P., Engel J., Sindermann H., Fischer C., Junge K., Bryceson A., Berman J. Oral miltefosine for Indian visceral leishmaniasis. N. Engl. J. Med. 2002, 347:1739-1746.
123. Sundar S., Jha T.K., Thakur C.P., Sinha P.K., Bhattacharya S.K. Injectable paromomycin for Visceral leishmaniasis in India. N. Engl. J. Med. 2007, 356:2571-2581.
124. Sundar S., Chakravarty J., Agarwal D., Rai M., Murray H.W. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N. Engl. J. Med. 2010, 362:504-512.
125. Sundar S., Singh A., Rai M., Prajapati V.K., Singh A.K., Ostyn B., Boelaert M., Dujardin J.C., Chakravarty J. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin. Infect. Dis. 2012, 55:543-550.
126. te Welscher Y.M., ten Napel H.H., Balague M.M., Souza C.M., Riezman H., de Kruijff B., Breukink E. Natamycin blocks fungal growth by binding specifically to ergosterol without permeabilizing the membrane. J. Biol. Chem. 2008, 283:6393-6401.
127. Tripathi P., Singh V., Naik S. Immune response to leishmania: paradox rather than paradigm. FEMS Immunol. Med. Microbiol. 2007, 51:229-242.
128. Urbina J.A., Concepcion J.L., Rangel S., Visbal G., Lira R. Squalene synthase as a chemotherapeutic target in Trypanosoma cruzi and Leishmania mexicana. Mol. Biochem. Parasitol. 2002, 125:35-45.
129. van Griensven J., Diro E. Visceral leishmaniasis. Infect. Dis. Clin. N. Am. 2012, 26:309-322.
130. van Zandbergen G., Klinger M., Mueller A., Dannenberg S., Gebert A., Solbach W., Laskay T. Cutting edge: neutrophil granulocyte serves as a vector for Leishmania entry into macrophages. J. Immunol. 2004, 173:6521-6525.
131. Verma N.K., Dey C.S. Possible mechanism of miltefosine-mediated death of Leishmania donovani. Antimicrob. Agents Chemother. 2004, 48:3010-3015.
132. Verweij J., Planting A., van der Burg M., Stoter G. A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumoursse. J. Cancer Res. Clin. Oncol. 1992, 118:606-608.
133. Von Jansco N., Von Jansco H. Chemotherapeutische wirkung und Kohlehydratstoffwechsel: die Heilwirking von Guanidinderivaten auf die Trypanosomeninfektion. Z. Immunitatsforsch. Exp. Ther. 1935, 86:1-30.
134. Wadhone P., Maiti M., Agarwal R., Kamat V., Martin S., Saha B. Miltefosine promotes IFN-gamma-dominated anti-leishmanial immune response. J. Immunol. 2009, 182:7146-7154.
135. Walker J., Saravia N.G. Inhibition of Leishmania donovani promastigote DNA topoisomerase I and human monocyte DNA topoisomerases I and II by antimonial drugs and classical antitopoisomerase agents. J. Parasitol. 2004, 90:1155-1162.
136. Webb J.R., McMaster W.R. Molecular cloning and expression of a Leishmania major gene encoding a single-stranded DNA-binding protein containing nine CCHC zinc finger motifs. J. Biol. Chem. 1993, 268:13994-14002.
137. Wong-Beringer A., Jacobs R.A., Guglielmo B.J. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin. Infect. Dis. 1998, 27:603-618.
138. Yardley V., Khan A.A., Martin M.B., Slifer T.R., Araujo F.G., Moreno S.N., Docampo R., Croft S.L., Oldfield E. In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii. Antimicrob. Agents Chemother. 2002, 46:929-931.
139. Zhou Y., Messier N., Ouellette M., Rosen B.P., Mukhopadhyay R. Leishmania major LmACR2 is a pentavalent antimony reductase that confers sensitivity to the drug pentostam. J. Biol. Chem. 2004, 279:37445-37451.
140. Zufferey R., Allen S., Barron T., Sullivan D.R., Denny P.W., Almeida I.C., Smith D.F., Turco S.J., Ferguson M.A., Beverley S.M. Ether phospholipids and glycosylinositolphospholipids are not required for amastigote virulence or for inhibition of macrophage activation by Leishmania major. J. Biol. Chem. 2003, 278:44708-44718.
141. Zuo X., Djordjevic J.T., Bijosono Oei J., Desmarini D., Schibeci S.D., Jolliffe K.A., Sorrell T.C. Miltefosine induces apoptosis-like cell death in yeast via Cox9p in cytochrome c oxidase. Mol. Pharmacol. 2011, 80:476-485.